- Home
- GCMG vs EVMN Comparison
GCMG vs EVMN Comparison
Compare GCMG & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCMG | EVMN |
|---|---|---|
| Founded | 1971 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.5M | 628.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | GCMG | EVMN |
|---|---|---|
| Price | $11.64 | $17.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $15.67 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 961.8K | 100.3K |
| Earning Date | 11-05-2025 | 12-11-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $543,085,000.00 | $13,000,000.00 |
| Revenue This Year | $6.58 | N/A |
| Revenue Next Year | $9.84 | N/A |
| P/E Ratio | $36.46 | ★ N/A |
| Revenue Growth | 17.40 | ★ 160.00 |
| 52 Week Low | $10.23 | $16.70 |
| 52 Week High | $14.48 | $24.03 |
Technical Indicators
Market Signals| Indicator | GCMG | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | N/A |
| Support Level | $10.47 | N/A |
| Resistance Level | $11.39 | N/A |
| Average True Range (ATR) | 0.31 | 0.00 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 92.11 | 0.00 |
Price Performance
Historical ComparisonAbout GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.